Publicaciones en las que colabora con Vicente Vicente García (24)

2022

  1. Molecular Dissection of Structural Variations Involved in Antithrombin Deficiency

    Journal of Molecular Diagnostics, Vol. 24, Núm. 5, pp. 462-475

2021

  1. A novel genetic variant in PTGS1 affects N-glycosylation of cyclooxygenase-1 causing a dominant-negative effect on platelet function and bleeding diathesis

    American Journal of Hematology

  2. Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)

    Scientific Reports

  3. Inherited platelet disorders: An updated overview

    International Journal of Molecular Sciences, Vol. 22, Núm. 9

2019

  1. Identification of novel variants in ten patients with Hermansky-Pudlak syndrome by high-throughput sequencing

    Annals of Medicine, Vol. 51, Núm. 2, pp. 141-148

  2. Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content

    Platelets, Vol. 30, Núm. 6, pp. 743-751

2018

  1. Identification of two novel mutations in RASGRP2 affecting platelet CalDAG-GEFI expression and function in patients with bleeding diathesis

    Platelets, Vol. 29, Núm. 2, pp. 192-195

  2. Introducing high-throughput sequencing into mainstream genetic diagnosis practice in inherited platelet disorders

    Haematologica, Vol. 103, Núm. 1, pp. 148-162

  3. Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia

    British Journal of Haematology, Vol. 182, Núm. 3, pp. 373-383

2017

  1. Clinical perspectives on the management of bleeding in patients on oral anticoagulants: The DECOVER Study (DElphi Consensus on oral COagulation and therapy action reVERsa

    Emergencias, Vol. 29, Núm. 1, pp. 18-26

  2. Wiskott–Aldrich syndrome in a child presenting with macrothrombocytopenia

    Platelets, Vol. 28, Núm. 4, pp. 417-420

2016

  1. Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method

    Annals of Hematology, Vol. 95, Núm. 5, pp. 719-732

  2. Identification of a new potential mechanism responsible for severe bleeding in myeloma: Immunoglobulins bind the heparin binding domain of antithrombin activating this endogenous anticoagulant

    Haematologica

  3. Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction

    Blood, Vol. 128, Núm. 9, pp. 1282-1289

  4. Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines

    Annals of Hematology, Vol. 95, Núm. 7, pp. 1089-1098

  5. Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria

    Medicina Clinica

2011

  1. Diagnóstico y tratamiento de la hemoglobinuria paroxística nocturna

    Medicina Clinica

2008

  1. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms

    Haematologica, Vol. 93, Núm. 5, pp. 729-734

2007

  1. Antithrombin Cambridge II (A384S): An underestimated genetic risk factor for venous thrombosis

    Blood, Vol. 109, Núm. 10, pp. 4258-4263

2006

  1. A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis

    Blood, Vol. 108, Núm. 1, pp. 177-183